Last update 09 Nov 2024
Neoantigen specific TCR-T cell drug product(Alaunos Therapeutics, Inc.)
Last update 09 Nov 2024
Overview
Basic Info
Drug Type TCR therapy |
Synonyms Neoantigen Targeted TCR-T |
Target |
Mechanism Tumor-associated antigen inhibitors(Tumor-associated antigen inhibitors), Gene transference, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with Neoantigen specific TCR-T cell drug product(Alaunos Therapeutics, Inc.)Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Using the Sleeping Beauty System to Express T Cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects With Solid Tumors
Phase I/II Study of Autologous T Cells Engineered Using the Sleeping Beauty System to Express T-Cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects With Solid Tumors
100 Clinical Results associated with Neoantigen specific TCR-T cell drug product(Alaunos Therapeutics, Inc.)
Login to view more data
100 Translational Medicine associated with Neoantigen specific TCR-T cell drug product(Alaunos Therapeutics, Inc.)
Login to view more data
100 Patents (Medical) associated with Neoantigen specific TCR-T cell drug product(Alaunos Therapeutics, Inc.)
Login to view more data
100 Deals associated with Neoantigen specific TCR-T cell drug product(Alaunos Therapeutics, Inc.)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Solid tumor | Phase 2 | - | 01 Apr 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | 6 | TCR-T cell | upoiefybcg(stkhrhdzyt) = rgibwzxbzu qzdyuhpnse (glyfttzaxq ) | Positive | 14 Aug 2023 | ||
Phase 1/2 | Neoplasms KRAS G12D Mutation | 1 | Cyclophosphamide+Fludarabine Phosphate+TCR-T | fqdruaeeli(yiegabcmuu) = Grade 4 thrombocytopenia and grade 3 anemia occurred and were both attributed to the lymphodepletion regimen. bnnnuuihwo (ionwuhudrg ) View more | Positive | 21 Sep 2022 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free